GlycoRNA-rich, neutrophil membrane-coated, siMT1-loaded nanoparticles mitigate abdominal aortic aneurysm progression by inhibiting the formation of neutrophil extracellular traps
Source abstract
Abstract
Abdominal aortic aneurysm (AAA) is a life-threatening vascular condition. Currently, there are no clinically available pharmacological interventions that can stop the progression of AAA, primarily due to the incomplete understanding of its pathogenesis and the absence of effective drug delivery systems. The present study aimed to develop a targeted therapy for AAA through a nanomedicine approach involving site-specific regulation of neutrophil extracellular trap (NET)-related pathological vascular remodeling. We found that metallothionein 1 (MT1) was upregulated in AAA lesions in both humans and mice. MT1 also facilitated the formation of NETs and subsequently induced phenotypic transformation and apoptosis in vascular smooth muscle cells. Additional in vivo studies revealed that the glycoRNA-rich membranes coated siMT1-loaded poly(lactic-co-glycolic acid) (PLGA)-polyethylene glycol (PEG) nanoparticles (GlycoRNA-NP-siMT1) effectively delivered siMT1 to AAA lesions, thereby inhibiting abdominal aortic dilation. Mechanistically, GlycoRNA-NP-siMT1 mitigated pathological remodeling of the abdominal aorta by reducing neutrophil infiltration and inhibiting the formation of NETs. Our study indicates that MT1 facilitates the progression of AAA by modulating the formation of NETs. Furthermore, GlycoRNA-NP-siMT1 show an inhibitory effect on AAA progression through a dual mechanism: they competitively inhibit neutrophil infiltration and release siMT1, which subsequently suppresses NET formation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Aortic aneurysm repair treatments · Infectious Aortic and Vascular Conditions · Neutrophil, Myeloperoxidase and Oxidative Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Abdominal aortic aneurysm: update on pathogenesis and medical treatments10.1038/s41569-018-0114-9 ↗
2. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines10.1161/CIR.0000000000001106 ↗
3. Abdominal aortic aneurysms10.1038/s41572-018-0030-7 ↗
4. Monocytes and macrophages in abdominal aortic aneurysm10.1038/nrcardio.2017.52 ↗
5. Gut microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation10.1016/j.chom.2022.09.004 ↗
6. Neutrophil extracellular traps in immunity and disease10.1038/nri.2017.105 ↗
7. Reducing abdominal aortic aneurysm progression by blocking neutrophil extracellular traps depends on thrombus formation10.1016/j.jacbts.2023.11.003 ↗
8. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems10.1039/C5CS00798D ↗
9. A multi-bioactive nanomicelle-based "one stone for multiple birds" strategy for precision therapy of abdominal aortic aneurysms10.1002/adma.202204455 ↗
10. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis10.1038/s41569-021-00629-x ↗
11. Netrin-1 monoclonal antibody-functionalized nanoparticle loaded with metformin prevents the progression of abdominal aortic aneurysms10.2147/IJN.S400993 ↗
12. Targeted treatment of ischemic stroke by bioactive nanoparticle-derived reactive oxygen species responsive and inflammation-resolving nanotherapies10.1021/acsnano.1c04753 ↗
13. Recent advances in targeted therapy for inflammatory vascular diseases10.1016/j.jconrel.2024.06.063 ↗
14. Small RNAs are modified with N-glycans and displayed on the surface of living cells10.1016/j.cell.2021.04.023 ↗
15. Cell surface RNAs control neutrophil recruitment10.1016/j.cell.2023.12.033 ↗
16. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML10.1038/s41375-019-0581-y ↗
17. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development10.1038/ncomms6214 ↗
18. RNA therapeutics for the cardiovascular system10.1161/CIRCULATIONAHA.123.067373 ↗
19. Peptide-siRNA nanoparticles targeting NF-kappaB p50 mitigate experimental abdominal aortic aneurysm progression and rupture10.1016/j.bioadv.2022.213009 ↗
20. Pathogenesis-guided rational engineering of nanotherapies for the targeted treatment of abdominal aortic aneurysm by inhibiting neutrophilic inflammation10.1021/acsnano.4c00120 ↗
21. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines10.1016/j.addr.2022.114417 ↗
22. Tea polyphenol nanoparticles enable targeted siRNA delivery and multi-bioactive therapy for abdominal aortic aneurysms10.1186/s12951-024-02756-2 ↗
23. Mesenchymal stem cell-derived extracellular vesicles protect against abdominal aortic aneurysm formation by inhibiting NET-induced ferroptosis10.1038/s12276-023-00986-2 ↗
24. Pathophysiology and epidemiology of abdominal aortic aneurysms10.1038/nrcardio.2010.180 ↗
25. The bioinorganic chemistry of mammalian metallothioneins10.1021/acs.chemrev.1c00371 ↗
26. The roles of metallothioneins in carcinogenesis10.1186/s13045-018-0645-x ↗
27. Metallothioneins as dynamic markers for brain disease in lysosomal disorders10.1002/ana.24053 ↗
28. Zinc protects against cadmium-induced toxicity in neonatal murine engineered cardiac tissues via metallothionein-dependent and independent mechanisms10.1038/s41401-019-0320-y ↗
29. Basal and oxidative stress-induced expression of metallothionein is decreased in ascending aortic aneurysms of bicuspid aortic valve patients10.1161/CIRCULATIONAHA.108.770776 ↗